

General Anesthesia Drugs Market | clear understanding of the present position of the market players

General Anesthesia Drugs Market North America would continue to maintain the lead over the analysis period

PORTLAND, OREGON, UNITED STATE, August 22, 2022 /EINPresswire.com/ -- According to a new report published by Allied Market Research, titled, "[General Anesthesia Drugs Market](#)," The general anesthesia drugs market size was valued at \$5.4 billion in 2021, and is estimated to reach \$7.7 billion by 2031,

growing at a CAGR of 3.5% from 2022 to 2031. General anesthesia drug is defined as state of controlled unconsciousness in which the anesthesiologist administers drug through a mask or an intravenous catheter placed in the vein. Mostly general anesthesia is used in long operations and painful surgical procedures. The primary goal of general anesthesia is to make a patient unconscious and unable to feel painful stimuli. The five main types of anesthetic agents include intravenous anesthetics, inhalational anesthetics, IV sedatives, synthetic opioids, and neuromuscular blocking. General anesthesia is most commonly used for major operations such as knee replacement surgery, hip replacement surgery, heart surgery, cancer surgery, and gastro-intestinal surgery.

Get Customized Report @ <https://www.alliedmarketresearch.com/request-sample/5627>

□□□ □□ □□ □□% □□□□□□□□, □□□□ □□□ □□□□ □□ □□□□□□ □□□□.

Increase in the number of general anesthesia drugs industry who manufacture general anesthesia propels the growth of the market. For instance, in April 2020, Hikma pharmaceutical Plc, a pharmaceutical company, announced the launch of vecuronium bromide for Injection, which is a new general anesthesia drug. It is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or



mechanical ventilation. Moreover, in May 2020, Hikma, also announced the launch of propofol injectable emulsion which is an intravenous general anesthesia drug used in surgical procedure.

The general anesthesia drug market is segmented on the basis type of drug, route of administration, surgery type, end user, and region.

On the basis of type of drug, the market is classified into propofol, sevoflurane, desflurane and others. The others segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to rise in the launch of novel general anesthesia drugs, and increase in number of approval for general anesthesia drugs.

On the basis of route of administration, the market is classified into intravenous and inhalation. The inhalation segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to rise in number of diagnostic procedure, and increase in government support regarding the use of inhalation anesthesia.

On the basis of surgery type, the market is classified into knee & hip replacements, heart surgeries, cancer surgery, general surgery. The knee & hip replacement segment dominated the market in 2021, and is expected to continue this trend during the forecast period, owing to increase in prevalence of osteoarthritis, rise in number of arthroplasty procedure, and increase in accident and sport related knee and hip injury.

The COVID-19 outbreak is anticipated to have a negative impact on growth of the general anesthesia drug market. The pandemic has stressed healthcare systems in the world and cause decline in the demand of general anesthesia drug due to canceled or postpone of elected surgeries. According to the report share by British Journal of Surgery in May 2020, it was reported that, approximately 28.4 million elected surgeries estimated to be canceled in 2020 over the globe. According to the report share by National Library Medicine in July 2020, after excluding emergency surgical procedures, it was estimated that about 30,000 primary and 3000 revision knee and hip replacement arthroplasty procedures was canceled each week in the U.S In current scenario, the number of surgeries which got cancelled or postponed during COVID-19 pandemic were rescheduled.

KEY FINDINGS OF THE STUDY

By type of drug, the others segment was the highest contributor to the market in 2021.

By route of administration, the inhalation segment was the highest contributor to the market in 2021.

By surgery type, the knee & hip replacement surgery segment dominated the market in 2021 and is expected to continue this trend during the forecast period.

By end user, the hospital segment was the highest contributor to the market in 2021.

By region, North America garnered the largest revenue share in 2021, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Key Market Segments

By TYPE OF DRUGS

Propofol

Sevoflurane

Desflurane

Others

By ROUTE OF ADMINISTRATION

Intravenous

Inhalation

By SURGERY TYPE

Knee and hip replacements

Heart surgeries

Cancer surgery

General surgery

Get Customized Report @ <https://www.alliedmarketresearch.com/request-for-customization/5627>

Key Market Players

B. Braun Melsungen

Baxter International Inc.

Fresenius SE and Co. KGaA

Hikma Pharmaceuticals plc

Paion AG

Pfizer Inc.

Abbott Laboratories

Abbvie Inc

AstraZeneca plc

Avet Pharmaceuticals Inc

We also Offers Regional and Country Reports-

Japan General Anesthesia Drugs Market

South Korea General Anesthesia Drugs Market

Singapore General Anesthesia Drugs Market

China General Anesthesia Drugs Market

Indonesia General Anesthesia Drugs Market

Australia General Anesthesia Drugs Market

Taiwan General Anesthesia Drugs Market

□□□□□ □□□□□□□□ □□□□□□□□:

[Intraoral Scanners Market](#)

[Ulcerative Colitis Market](#)

About Us

Allied Market Research (AMR) is a market research and business-consulting firm of Allied Analytics LLP, based in Portland, Oregon. AMR offers market research reports, business solutions, consulting services, and insights on markets across 11 industry verticals. Adopting extensive research methodologies, AMR is instrumental in helping its clients to make strategic business decisions and achieve sustainable growth in their market domains. We are equipped with skilled analysts and experts, and have a wide experience of working with many Fortune 500 companies and small & medium enterprises.

David Correa
Allied Analytics LLP
800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/587173530>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 Newsmatics Inc. All Right Reserved.